Pivotal Study of E 2087 (Eisai) shows positive results in treating Epilepsy - 20-Apr-2012

A pivotal Phase III study of E 2087 (perampanel), from Eisai, developed as an adjunctive therapy for partial seizures in adult patients with Epilepsy, provides evidence that 4 and 8 mg/day doses of the drug are effective and well-tolerated in reducing uncontrolled partial-onset seizures when compared with placebo. Efficacy in seizure reduction was seen despite treatment with up to three other anti-epilepsy drugs. See: "Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures." G.L. Krauss et al. Neurology, April 18 2012 DOI: 10.1212/WNL.0b013e318254473

Related News

Related Neurological Disorders Information

Related Neurological Disorders Drugs

Back to top

Latest News

10 May 2015
19 May 2013
19 May 2013